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Creatine  was previously  shown  to produce  an  antidepressant-like  effect  in  the  tail  suspension  test  through
a  modulation  of  the  dopaminergic  system.  In this  study,  the mechanisms  underlying  its  antidepressant-
like  effect  were  further  evaluated  by  investigating  the involvement  of the  serotonergic  system  in its
effect.  The  anti-immobility  effect  of  creatine  (1  mg/kg)  was  prevented  by  the  pretreatment  of  mice  with
p-chlorophenylalanine  methyl  ester  (PCPA;  100  mg/kg,  i.p.,  for  4  consecutive  days,  an  inhibitor  of  sero-
tonin (5-HT)  synthesis).  Creatine  (0.01  mg/kg,  sub-effective  dose)  in  combination  with  sub-effective  doses
of WAY100635  (0.1  mg/kg,  s.c.,  a 5-HT1A receptor  antagonist),  8-OH-DPAT  (0.1  mg/kg,  i.p., a 5-HT1A recep-reatine
erotonergic system
ail suspension test
tor  agonist)  or selective  serotonin  reuptake  inhibitors  ﬂuoxetine  (5 mg/kg,  p.o.),  paroxetine  (0.1  mg/kg,
p.o.),  citalopram  (0.1  mg/kg,  p.o.)  and  sertraline  (3 mg/kg,  p.o.)  reduced  the  immobility  time  in the  tail
suspension  test  as compared  with  either  drug  alone.  These  results  indicate  that the  antidepressant-like
effect  of  creatine  is likely  mediated  by an  interaction  with  5-HT1A receptors.  Of note,  the  present  results
also  indicate  that  creatine  improves  the  effectiveness  of the  selective  serotonin  reuptake  inhibitors,  a
rapeﬁnding  that  may  have  the
. Introduction
Creatine, a substrate for cytosolic and mitochondrial creatine
inases, is a precursor of phosphocreatine (Andres et al., 2008). The
reatine kinase/phosphocreatine system seems to play a complex,
ulti-faceted role in brain energy homeostasis by maintaining
igh ADP levels at the site in mitochondria at which ATP is gen-
rated and low levels at the site of ATP utilization (Bessman
nd Carpenter, 1985; Wyss et al., 1992). A growing number of
eports have provided evidence for the importance of the crea-
ine kinase/phosphocreatine system and creatine metabolism for
aintaining energy homeostasis in brain. In addition, this system
as been also implicated in the pathophysiology of depression,
ince: (i) brain phosphocreatine, detected by phosphorus-31 mag-
etic resonance spectroscopy, decreased in severely depressed
atients (Kato et al., 1992); (ii) an inverse correlation between
amilton Depression Rating Scale scores and white matter crea-
ine levels was shown (Dager et al., 2004); (iii) single prolonged
Abbreviations: ANOVA, analysis of variance; 8-OH-DPAT, (+)-8-hydroxy-2-(di-
-propylamino)tetralinHBr; FST, forced swimming test; 5-HT, serotonin; PCPA, p-
hlorophenylalanine methyl ester; SSRI, selective serotonin reuptake inhibitor; TST,
ail  suspension test; WAY100635, N-N-(2-pyridynyl) cyclohexanecarboxamide.
∗ Corresponding author. Tel.: +55 48 3721 5043; fax: +55 48 3721 9672.
E-mail addresses: analucia@mbox1.ufsc.br, alsrodri@gmail.com
A.L.S. Rodrigues).
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Open access under the Elsevier OA license.utic  implications  for  the  treatment  of depressive  disorders.
© 2013 Elsevier Inc. 
stress and forced swimming stress decreased creatine concentra-
tions in the rat prefrontal cortex (Herring et al., 2008; Kim et al.,
2010; Knox et al., 2010); (iv) learned helplessness, a well validated
animal model of depression, decreased the hippocampal creatine
transporter expression as compared to wild type animals and the
selective serotonin reuptake inhibitor escitalopram blocked this
effect (Lugenbiel et al., 2010); (v) some antidepressants such as
paroxetine and imipramine increase creatine kinase activity (Assis
et al., 2009; Reus et al., 2012a,b; Santos et al., 2009); (vi) agents
that exert antidepressant action cause changes in brain levels of
creatine-containing compounds, such as S-adenosyl-l-methionine
that, in turn, increases phosphocreatine brain levels (Papakostas,
2009; Papakostas et al., 2003; Silveri et al., 2003).
Several clinical trials (Amital et al., 2006; Kondo et al., 2011;
Lyoo et al., 2012) and studies with animal models (Allen et al., 2010,
2012; Cunha et al., 2012) have reported that creatine supplemen-
tation exerts antidepressant effects. Speciﬁcally, it was recently
demonstrated that the administration of creatine produces an
antidepressant-like effect in the tail suspension test, a predictive
test of antidepressant properties frequently used to evaluate the
efﬁcacy of drugs designed to treat depression, and this effect was
shown to be mediated by a dopaminergic activation (Cunha et al.,
2012). Taking into account that microdialysis studies have clearly
Open access under the Elsevier OA license.shown that exposure of the striatum or nucleus accumbens to sero-
tonin results in increased release of dopamine (Yadid et al., 1994;
Dremencov et al., 2004) and that drugs that enhance serotonergic
neurotransmission, such as those that inhibit serotonin reuptake at
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erve terminals, or its metabolism (monoamine oxidase inhibitors)
re effective in treating depression, in the present study the role of
he serotonergic system in the antidepressant-like effect of creatine
n the TST was investigated.
There is accumulating evidence for a critical involvement of
erotonergic receptors, particularly 5-HT1A, in the pathophysi-
logy and treatment of depression (Hensler, 2002; Middlemiss
t al., 2002). In animal studies, 5-HT1A agonists increase pre-
rontal dopamine release (Díaz-Mataix et al., 2005; Bantick et al.,
005). Therefore, we hypothesized that 5-HT1A receptors could be
nvolved in the antidepressant-like effect of creatine in the TST.
Furthermore, another aim of this study was to investigate
he possibility that the combined administration of sub-effective
oses of creatine and serotonin reuptake inhibitors ﬂuoxe-
ine, paroxetine, citalopram and sertraline causes a synergistic
ntidepressant-like effect in the TST. This is an approach that has
otential therapeutic relevance, considering that the clinical aim
f combining selective serotonin reuptake inhibitors with a phar-
acological agent is to increase the antidepressant efﬁcacy while
educing side effects (Nelson, 2007).
. Materials and methods
.1. Animals
Male Swiss mice (30–40 g, 60–75 days) were used in the present study. Mice
ere housed in groups of fourteen animals per plastic cage under controlled condi-
ions of light (from 07:00 to 19:00 h) and temperature (21 ± 1 ◦C). Mice were allowed
ree access to standard laboratory food and tap water, and to adapt to the laboratory
nvironment for at least 1 week before the behavioral studies. Each experimental
roup consisted of 8–10 animals. Animals were randomly distributed into speci-
ed  experimental groups. All manipulations were carried out between 14:00 and
7:00 h, with each animal used only once. All procedures in this study were per-
ormed in accordance with the National Institute of Health Guide for the Care and
se  of Laboratory Animals and approved by the Ethics Committee of the Institution.
ll  efforts were made to minimize animals suffering and to reduce the number of
nimals used in the experiments.
.2. Drugs
The following drugs were used: creatine monohydrate, p-chlorophenylalanine
ethyl ester (PCPA), N-N-(2-pyridynyl) cyclohexanecarboxamide (WAY100635),
+)-8-hydroxy-2-(di-n-propylamino)tetralinHBr (8-OH-DPAT) (Sigma Chemical Co.,
SA), ﬂuoxetine hydrochloride, sertraline hydrochloride, paroxetine hydrochloride
Pﬁzer, Brazil), citalopram bromidrate (LIBBS Farmacêutica Ltda., Brazil). All drugs
ere dissolved in saline, except creatine, ﬂuoxetine, sertraline, paroxetine, citalo-
ram which were dissolved in distilled water. All drugs were administered by
ntraperitoneal (i.p.) route, except creatine, ﬂuoxetine, sertraline, paroxetine and
italopram which were administered by oral route (p.o.) by gavage and WAY100635
hat was administered by subcutaneous route (s.c.). All drugs were administered in
 constant volume of 10 ml/kg body weight.
.3. Experimental design
In order to investigate a possible contribution of the 5-HT system to the effect of
reatine in reducing the immobility time in the TST, animals were pretreated with
CPA (100 mg/kg, i.p., an inhibitor of serotonin synthesis) or vehicle, once a day,
or four consecutive days. Then, 24 h after the last PCPA or saline injection, animals
ere treated with creatine (1 mg/kg, p.o.), ﬂuoxetine (10 mg/kg, p.o., a serotonin
euptake inhibitor, positive control) or vehicle and were tested in the TST open-ﬁeld
est 60 min later.
In another set of experiments, a sub-effective dose of creatine (0.01 mg/kg, p.o.)
r  vehicle was  administered 30 min  before administration of a sub-effective dose of
-OH-DPAT (1 mg/kg, i.p., a 5-HT1A receptor agonist), WAY100635 (0.1 mg/kg, s.c.,
 5-HT1A receptor antagonist) or vehicle. Thirty minutes later, the TST was  carried
ut.
In  order to investigate the potential synergistic effect of sub-effective doses
f creatine with sub-effective doses of selective 5-HT reuptake inhibitors (ﬂuox-
tine, paroxetine, sertraline and citalopram) in the TST or open-ﬁeld test, creatine
r  vehicle administration was followed by another immediate administration of the
ntidepressant drug or vehicle 60 min  before the TST or open-ﬁeld test.In  order to establish the effective and sub-effective doses of serotonin receptor
gonist 8-OH-DPAT, mice were administered intraperitoneally with 8-OH-DPAT at
oses 0.1–1 mg/kg and 30 min later were submitted to the TST or open-ﬁeld test.
n  order to establish the effective and sub-effective doses of selective serotonin
euptake inhibitors, mice were administered orally with citalopram and sertraline at Bulletin 95 (2013) 61– 69
doses: 0.1–10 mg/kg and 3–30 mg/kg, respectively, and 60 min later were submitted
to  the TST or open-ﬁeld test.
The effective (1 mg/kg) and subeffective (0.01 mg/kg) doses of creatine were
selected on the basis of previous study from our laboratory (Cunha et al., 2012)
and  the doses of the serotonergic agents (PCPA, WAY  100635, 8-OH-DPAT, and the
selective serotonin reuptake inhibitors) were selected on the basis of literature data
and on previous results from our laboratory (Brocardo et al., 2008; Cunha et al., 2008;
Kaster et al., 2005; Machado et al., 2009; O’Leary et al., 2007; O’Neill and Conway,
2001).
2.4. Behavioral tests
2.4.1. Tail suspension test (TST)
The TST has become one of the most widely used models for assessing
antidepressant-like activity in mice. The test is based on the fact that animals sub-
jected to the short-term inescapable stress of being suspended by their tail, will
develop an immobile posture. The total duration of immobility induced by tail sus-
pension was measured according to the method described by Steru et al. (1985).
Brieﬂy, mice both acoustically and visually isolated were suspended 50 cm above
the ﬂoor by adhesive tape placed approximately 1 cm from the tip of the tail. Immo-
bility time was  recorded during a 6 min period. Mice were considered immobile
only when they hung passively and completely motionless. The immobility time
was recorded by observers blind to the drug treatment (Cunha et al., 2008; Machado
et al., 2009).
2.4.2. Open-ﬁeld test
To assess the possible effects of creatine on locomotor activity, mice were eval-
uated in the open-ﬁeld paradigm as previously described by Machado et al. (2009).
Mice were individually placed in a wooden box (40 cm × 60 cm × 50 cm) with the
ﬂoor divided into 12 equal rectangles. The number of rectangles crossed by the mice
with its four paws (crossing) was registered during a period of 6 min. The number
of  crossings was  considered as indicative of locomotor activity. The behavior was
recorded by observers blind to the drug treatment.
2.5. Statistical analysis
Comparisons between experimental and control groups were performed by one-
way  (dose–response curve of 8-OH-DPAT, sertraline and citalopram) or two-way
(investigation of serotonergic system modulation in the antidepressant-like effect of
creatine) ANOVA followed by Tukey’s HSD test when appropriate. A value of P < 0.05
was considered to be signiﬁcant.
3. Results
3.1. Inﬂuence of pretreatment with PCPA on the effect of creatine
in the TST and open-ﬁeld test
The result depicted in Fig. 1A shows that creatine at the dose
of 1 mg/kg, p.o. reduced the immobility time in the TST in mice
pretreated with vehicle, conﬁrming previous data from our group
(Cunha et al., 2012). Moreover, this anti-immobility effect of crea-
tine (1 mg/kg, p.o.) was  prevented by pretreatment of mice with
the inhibitor of serotonin synthesis (100 mg/kg, i.p., for 4 con-
secutive days). A two-way ANOVA showed signiﬁcant differences
for PCPA treatment (F(1,43) = 43.33; P < 0.01), creatine treatment
(F(2,43) = 4.79; P < 0.05) and PCPA × creatine treatment interaction
(F(2,43) = 8.36; P < 0.01). The number of crossings in open-ﬁeld test
was not altered by the pretreatment with PCPA and creatine treat-
ments (P > 0.05; Fig. 1B).
3.2. Effect 8-OH-DPAT on the immobility time in the tail
suspension test and on the number of crossings in the open-ﬁeld
test
The effect of acute administration of 8-OH-DPAT, a 5-HT1 recep-
tor agonist, at the dose range 0.1–1 mg/kg, i.p. on the immobility
time in the TST is shown in Fig. 2A. This agonist administered
at doses of 0.5–1 mg/kg reduced the immobility time (20.8% and
34.2% of reduction, respectively). However, 8-OH-DPAT adminis-
tered at a dose of 0.1 mg/kg did not reduce the immobility time
(Fig. 2A). The one-way ANOVA revealed a signiﬁcant effect of
8-OH-DPAT treatment (F(3,34) = 11.45; P < 0.01). Considering this
result, the sub-effective dose of 0.1 mg/kg was chosen to be used in
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Fig. 1. The 5-HT depletion abolishes the antidepressant-like effect of creatine.
Effect of pretreatment of mice with PCPA (100 mg/kg, i.p., a tryptophan hydroxy-
lase inhibitor) and treatment with creatine (1 mg/kg, p.o.) on the immobility time
in  the TST (Panel A) and on the number of crossings in the open-ﬁeld test (Panel
B).  Each column represents the mean ± S.E.M. **P < 0.01 compared with the vehicle-
t
(
s
c
D
T
d
n
(
3
e
a
a
d
Fig. 2. The activation of 5-HT1A receptors produces an antidepressant-like effect
in  the tail suspension test. Effect of treatment with 8-OH-DPAT (0.1 mg/kg, i.p., a
5-HT1A receptor agonist) on the immobility time in the TST (Panel A) and number
of  crossings in the open-ﬁeld test (Panel B) in mice. Each column represents thereated control; #P < 0.01 as compared with the same group pretreated with vehicle
two-way ANOVA followed by Tukey’s HSD post hoc test).
ubsequent studies related to the interaction of 8-OH-DPAT with
reatine in the TST. Furthermore, mice administered with 8-OH-
PAT at doses of 0.1–1 mg/kg, i.p. was tested in the open-ﬁeld test.
he administration of 8-OH-DPAT at the doses 0.1 and 0.5 mg/kg
id not affect the locomotor activity of mice, but decreased the
umber of crossings in the open-ﬁeld test at the dose of 1 mg/kg
F(3,32) = 5.40; P < 0.01; Fig. 2B).
.3. Involvement of 5-HT1 receptor in the antidepressant-like
ffect of creatineWAY100635, a 5-HT1 receptor antagonist, administered
t a sub-effective dose (0.1 mg/kg, s.c.) exhibited a potent
ntidepressant-like effect when combined with a sub-effective
ose of creatine (0.01 mg/kg, p.o.) in the TST as compared tomean ± S.E.M. *P < 0.05, **P < 0.01 compared with the vehicle-treated control (one-
way ANOVA followed by Tukey’s HSD post hoc test).
the control group or either drug alone (Fig. 3A). A two-way
ANOVA showed signiﬁcant differences for creatine treatment
(F(1,32) = 19.35; P < 0.01), WAY100635 treatment (F(1,32) = 7.68;
P < 0.05), and creatine × WAY100635 interaction (F(1,32) = 26.90;
P < 0.01). The number of crossings in open-ﬁeld test was not altered
by the administration of creatine and/or WAY100635 (P > 0.05;
Fig. 3C).
The administration of 8-OH-DPAT at a sub-effective dose
(0.1 mg/kg, i.p.) caused an antidepressant-like effect when com-
bined with a sub-effective dose of creatine (0.01 mg/kg, p.o.), as
compared to the control or either drug alone (Fig. 3B). A two-
way ANOVA showed signiﬁcant differences for creatine treatment
(F(1,29) = 11.32; P < 0.01), 8-OH-DPAT treatment (F(1,29) = 6.67;
P < 0.05), and creatine × 8-OH-DPAT interaction (F(1,29) = 7.86;
P < 0.05). The number of crossings in open-ﬁeld test was not altered
by the administration of creatine and/or 8-OH-DPAT (P > 0.05;
Fig. 3D).
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Fig. 3. Involvement of 5-HT1A receptor in the antidepressant-like effect of creatine. Effect of the treatment with sub-effective doses of creatine (0.01 mg/kg, p.o.) in combination
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espectively) and on the number of crossings in the open-ﬁeld test (Panels C and D
ehicle-treated control (two-way ANOVA followed by Tukey’s HSD post hoc test).
.4. Effect of acute treatment with citalopram and sertraline on
he immobility time in the TST and on the number of crossings in
he open-ﬁeld test
Citalopram administration by p.o. route at doses of 1 and
0 mg/kg reduced the immobility time in the TST in mice, but
id not alter the immobility time when administered at a dose
f 0.1 mg/kg (Fig. 4A). The one-way ANOVA revealed a signiﬁcant
ffect of citalopram treatment (F(3,28) = 17.20; P < 0.01). Sertraline
t doses of 3 and 10 mg/kg did not affect the immobility time in
he TST, but caused a reduction in the immobility time at dose of
0 mg/kg, p.o. (Fig. 4B). The one-way ANOVA revealed a signiﬁcant
ffect of sertraline treatment in mice (F(3,29) = 13.86; P < 0.01).
Furthermore, citalopram at the dose range 0.1–10 mg/kg, p.o.
nd sertraline (3–30 mg/kg, p.o.) were tested in the open-ﬁeld test
n mice. The administration of citalopram or sertraline did not alter
he number of crossings in the open-ﬁeld test (P > 0.05; Fig. 4C and
, respectively).
.5. Effect of the interaction of creatine with selective serotonin
euptake inhibitors on the immobility time in the TST and on the
umber of crossings in the open-ﬁeld test
Fluoxetine administered at a sub-effective dose (5 mg/kg,
.o.) exhibited a potent antidepressant-like effect when com-
ined with a sub-effective dose of creatine (0.01 mg/kg, p.o.)
n the TST as compared with the control or either drug alone
Fig. 5A). A two-way ANOVA showed signiﬁcant differences forp., a 5-HT1A receptor agonist) on the immobility time in the TST (Panels A and B,
ectively). Each column represents the mean ± S.E.M. **P < 0.01 compared with the
ﬂuoxetine treatment (F(1,29) = 22.22; P < 0.01), creatine treat-
ment (F(1,29) = 6.73; P < 0.01) and ﬂuoxetine × creatine interaction
(F(1,29) = 10.71; P < 0.01). Moreover, the number of crossings in
open-ﬁeld test was  not altered by the administration of creatine
and/or ﬂuoxetine (P > 0.05; Fig. 6A).
Paroxetine administered at a sub-effective dose (0.1 mg/kg,
p.o.) produced an antidepressant-like effect when combined with
a sub-effective dose of creatine (0.01 mg/kg, p.o.) in the TST as
compared with control or either drug alone (Fig. 5B). A two-way
ANOVA showed signiﬁcant differences for paroxetine treat-
ment (F(1,28) = 4.59; P < 0.05), creatine treatment (F(1,28) = 6.72;
P < 0.05), and paroxetine × creatine interaction (F(1,28) = 6.24;
P < 0.05). The number of crossings in open-ﬁeld test was not altered
by the administration of creatine and/or paroxetine (P > 0.05;
Fig. 6B).
Additionally, the selective serotonin reuptake inhibitor citalo-
pram administered at a sub-effective dose (0.1 mg/kg, p.o.)
exhibited antidepressant-like effect when combined with a sub-
effective dose of creatine (0.01 mg/kg, p.o.) in the TST as compared
with the control group or either drug alone (Fig. 5C). A two-way
ANOVA showed signiﬁcant differences for citalopram treatment
(F(1,30) = 6.77; P < 0.01), creatine treatment (F(1,30) = 4.60; P < 0.05)
and citalopram × creatine interaction (F(1,30) = 10.53; P < 0.05). The
number of crossings in open-ﬁeld test was not altered by the
administration of creatine and/or citalopram (P > 0.05; Fig. 6C).
Fig. 6D shows that sertraline administered at a sub-effective
dose (3 mg/kg, p.o.) caused an antidepressant-like effect when
combined with a sub-effective dose of creatine (0.01 mg/kg,
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Fig. 4. The antidepressant-like properties of selective serotonin reuptake inhibitors. Effect of treatment with citalopram (0.1 mg/kg, p.o.) or sertraline (3–30 mg/kg, p.o.)
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mn  the immobility time in the TST (Panels A and B, respectively) and number of cro
ean  ± S.E.M. *P < 0.05; **P < 0.01 compared with the vehicle-treated control (one-w
.o.) in the TST as compared with control group or either
rug alone (Fig. 6D). A two-way ANOVA showed signiﬁcant
ifferences for sertraline treatment (F(1,32) = 29.42; P < 0.01), crea-
ine treatment (F(1,32) = 10.06; P < 0.01), and sertraline × creatine
nteraction (F(1,32) = 5.23; P < 0.05). The number of crossings in
pen-ﬁeld test was not altered by the administration of creatine
nd/or sertraline (P > 0.05; Fig. 6D).
. Discussion
The high prevalence of depression, the fact that a signiﬁcant pro-
ortion of individuals do not respond well to any currently used
ntidepressant and the side effects elicited by these drugs sup-
ort the need for new therapeutics to treat this disorder (Wong
nd Licinio, 2001). In this context emerges creatine, a safe and
ell-tolerated dietary supplement that has been reported to exert
ntidepressant effects in animal models (Allen et al., 2010; Cunha
t al., 2012) and clinical trials (Kondo et al., 2011; Lyoo et al., 2012).
eregulations on the serotonergic system are implicated in the
athogenesis of depression and most of the currently available
ntidepressants cause activation of serotonergic neurotransmis-
ion (Elhwuegi, 2004; Millan, 2004). Thus, we hypothesized that
he antidepressant-like effect of creatine in the TST in mice could
e mediated by an activation of the serotonergic system.
In the ﬁrst set of experiments we investigated whether the
retreatment of mice with PCPA, an inhibitor of the enzyme tryp-
ophan hydroxylase, was able to abolish the antidepressant-like
ffect of creatine in the TST. PCPA was reported to produce a sig-
iﬁcant depletion of cortical 5-HT content in rats (93%) and mice
67–70%) (Cesana et al., 1993; O’Leary et al., 2007; Page et al., 1999).
he results presented herein clearly show that the pretreatment of
ice with PCPA abolished the anti-immobility effect of creatines in the open-ﬁeld test (Panels C and D, respectively). Each column represents the
NOVA followed by Tukey’s HSD post hoc test).
and ﬂuoxetine, a positive control, in the TST. The administration of
PCPA at the same dose employed in the present study reversed
the antidepressant-like action of ﬂuoxetine in the forced swim-
ming test (FST) (Brocardo et al., 2008; Kaster et al., 2005) and in
TST (Machado et al., 2009; Rodrigues et al., 2002), but was  not able
to reverse the antidepressant-like effect of imipramine in the TST
(Rodrigues et al., 2002). The reversal of the effect of creatine by the
depletion of 5-HT elicited by PCPA suggests that the antidepressant-
like effect of creatine is dependent on the bioavailability of 5-HT in
the synaptic cleft, similar to ﬂuoxetine. In line with this notion,
creatine supplementation causes an antidepressant-like effect in
the FST in rats by increasing swimming time, a behavioral proﬁle
associated with a serotonergic mechanism of action (Allen et al.,
2010). Furthermore, the treatment with acetyl-l-carnitine, com-
pound endowed with antidepressant-like properties in the FST,
increases the phosphocreatine and the phosphocreatine/creatine
ratio associated with increases in the levels of 5-HT in the cere-
bral cortex of mice (Di Cesare Mannelli et al., 2011; Pulvirenti et al.,
1990; Smeland et al., 2012).
The 5-HT1A receptor has been increasingly associated with
alterations in mood and emotion and has opposing functions as
a pre-synaptic somatodendritic autoreceptor and a post-synaptic
heteroreceptor (Albert, 2012). Indeed, the involvement of 5-HT1A
receptors in the mechanism of action of many classes of antide-
pressant drugs, including tricyclics, selective serotonin reuptake
inhibitors and monoamine oxidase inhibitors have been shown
(Hensler, 2002). The blockade of 5-HT1A autoreceptors enhances
presynaptic serotonergic function by preventing self-inhibitory
actions of 5-HT on the ﬁring and release of serotonergic neu-
rons, without hindering postsynaptic hippocampal responses that
contribute to an antidepressant-like effect (Artigas et al., 1994,
1996). Accordingly, clinical studies have demonstrated that the
co-administration of a 5-HT1A antagonist combined with selective
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Fig. 5. A sub-effective dose of creatine produces antidepressant-like effect in the TST when combined with a sub-effective dose of selective serotonin reuptake inhibitors.
Effect  of the treatment with sub-effective doses of creatine (0.01 mg/kg, p.o.) in combination with ﬂuoxetine (1 mg/kg, p.o.) or paroxetine (0.1 mg/kg, p.o.) or citalapram
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e0.1  mg/kg, p.o.) or sertraline (3 mg/kg, p.o.) on the immobility time in the TST (P
*P  < 0.01 compared with the vehicle-treated control (two-way ANOVA followed by
erotonin reuptake inhibitors accelerates the onset of the antide-
ressant effect (Artigas et al., 1994). The present results indicate an
nvolvement of 5-HT1A receptors in the antidepressant-like effect
f creatine in the TST. The ﬁrst piece of evidence to support this
ssumption is that the administration of WAY100635 potentiated
he antidepressant-like action of a sub-effective dose of creatine in
he TST. WAY100635 is a 5-HT1A receptor antagonist that synergis-
ically potentiates the increments of extracellular 5-HT produced
y serotonergic antidepressants (Romero et al., 1996). In line with
ur ﬁndings, the combined administration of WAY100635 with a
ub-effective dose of antidepressant compounds, including ﬂuox-
tine, signiﬁcantly reduced the immobility time in the FST in rats
Tatarczynska et al., 2002) and mice (Brocardo et al., 2008; Kaster
t al., 2005; Zomkowski et al., 2004). One possibility that could
ccount for the potentiation of the effect of creatine in the TST by
AY100635 is that the blockade of presynaptic 5-HT1A autorecep-
ors with the consequent increase on 5-HT release caused by this
ntagonist could potentiate the likely increase on 5-HT availability
nduced by creatine, causing an antidepressant-like effect. Never-
heless, we should take into account that WAY100635 is currently
escribed as a potent full agonist at the dopamine D4 receptors,
ut it is tenfold selective in its afﬁnity for 5-HT1A receptors over
opamine D4 receptors (Chemel et al., 2006).The postsynaptic 5-HT1A heteroreceptors that are abundant
eceptors in the central nervous system mediate 5-HT actions on
arget neurons and have been implicated in regulation of mood,
motion and stress responses (Albert, 2012). Here we show the A, B, C and D, respectively). Each column represents the mean ± S.E.M. *P < 0.05;
y’s HSD post hoc test).
5-HT1A receptor agonist 8-OH-DPAT administered at higher doses
elicited an antidepressant-like effect in the TST, in agreement with
the reported reduction in the immobility time caused by this
agonist in the FST in mice and rats (Lopez-Rubalcava and Lucki,
2000; O’Neill and Conway, 2001). Noteworthy, treatment with the
serotonergic neurotoxins 5,7-dihydroxytryptamine or PCPA, which
are proposed to act presynaptically, had no effect on the anti-
immobility response of 8-OH-DPAT in the FST, suggesting that
the postsynaptic 5-HT1A receptors mediate the antidepressant-like
effect of this agonist (Luscombe et al., 1993). Moreover, 8-OH-DPAT
has been shown to augment the activity of antidepressants in FST
(Redrobe et al., 1996), possibly via activation of post-synaptic 5-
HT1A receptors. Indeed, activation of postsynaptic 5-HT1A receptors
produces changes similar to those of conventional antidepressants
(Lucki, 1991). Taking these ﬁndings into account, the synergistic
antidepressant-like effect observed when mice were treated with
subeffective doses of creatine and 8-OH-DPAT suggest that an acti-
vation of postsynaptic 5-HT1A receptors is likely implicated in the
effect of creatine in the TST. It is possible to suppose that creatine
activates some intracellular signaling pathways downstream to
postsynaptic 5-HT1A, as protein kinase C and extracellular-signal-
regulated kinases (Mogha et al., 2012), but we  cannot rule out the
possibility that creatine may  directly interact with 5-HT1A recep-
tor. However, 8-OH-DPAT is also described as an agonist at the
5-HT7 receptors (Sprouse et al., 2004) and as a serotonin reuptake
inhibitor (Assié and Koek, 1996), targets that may  also mediate the
antidepressant-like effect of creatine.
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Fig. 6. Selective serotonin reuptake inhibitors or its combination with creatine did not alter the ambulation of mice in the open ﬁeld test. Effect of the treatment with
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f  crossings in the open-ﬁeld test (Panels A, B, C and D, respectively). Each column 
The selective serotonin reuptake inhibitors are the antidepres-
ants most prescribed all over the world (Stahl, 1998), although
heir use cause side effects such as sexual dysfunction, sleepiness,
nd weight gain (Cascade et al., 2009). However, combinations
f antidepressants with various substances may  increase their
fﬁcacy while minimizing the side effects (Nelson, 2007). In the
resent study, we investigated the effects of the combined oral
dministration of selective serotonin reuptake inhibitors with crea-
ine, all at doses that per se produce no antidepressant-like effect in
he TST. Interestingly, synergistic antidepressant-like effects of cre-
tine with ﬂuoxetine, paroxetine, citalopram and sertraline were
hown. Accordingly, a recent study demonstrated that creatine pro-
uced a synergistic antidepressant-like effect with ﬂuoxetine in
he FST in rats (Allen et al., 2012). Moreover, our ﬁnding is in line
ith a clinical study which reported that ﬂuoxetine and creatine
ombined therapy with for eight weeks produced an increase in
rain phosphocreatine concentration associated with a decline on
he scores of depression rating scale in female adolescents with
elective serotonin reuptake inhibitors-resistant major depressive
isorder (Kondo et al., 2011; Lyoo et al., 2012). Noteworthy, our
tudy clearly extends literature data by showing that besides pro-
ucing a synergistic antidepressant action with ﬂuoxetine, creatine
lso exerts this effect with paroxetine, citalopram and sertraline, a
nding that may  have therapeutic implication.
It is known that depression is common in the context of autoim-
une and inﬂammatory diseases and is frequently associated with
ersistently raised levels of proinﬂammatory cytokines and other
arkers of inﬂammation (Maes et al., 2012). Of note, 5-HT inhibits
he proinﬂamatory cytokine TNF- production (Cloëz-Tayarani
t al., 2003) and WAY100635 and 8-OH-DPAT markedly enhancedg/kg, p.o.), citalopram (0.1 mg/kg, p.o.) or sertraline (3 mg/kg, p.o.) on the number
ents the mean ± S.E.M.
the antidepressant effect of ﬂuoxetine at the subeffective dose on
the interferon--treated mice in the forced swimming test (Zhang
et al., 2010). In addition, creatine is also able to reduce plasma
proinﬂammatory cytokines levels (interleukin-1, interleukin-6,
tumor necrosis factor- and interferon-) in an inﬂammatory
condition (after a half-ironman competition), suggesting an anti-
inﬂamatory property of creatine. Then, a possibility to account for
our results is that creatine supplementation may modulate inﬂam-
matory parameters via the serotonergic system, a hypothesis that
needs future investigation.
Taking into account that we  have previously shown that the
antidepressant-like effect of creatine is mediated by dopaminer-
gic activation (Cunha et al., 2012) and considering that ﬂuoxetine
seems to inﬂuence the dopaminergic neurotransmission (Penttilä
et al., 2004), we  also cannot rule out the possibility that an interac-
tion of the serotoninergic and dopaminergic systems could play a
role in the antidepressant-like effect of creatine.
5. Conclusions
In conclusion, the results presented herein indicate that the
antidepressant-like action of creatine seems to be mediated by a
stimulation of the post-synaptic 5-HT1A receptors and an inhibition
of presynaptic 5-HT1A autoreceptors. Therefore, we  suggest that
creatine could be used alone or in combination with antidepres-
sant compounds in depression associated with hyposerotonergic
dysfunction. Although the results presented here should be taken
with care, they warrant future work focusing on the hypothesis
that a combination of creatine with selective serotonin reuptake
inhibitors can be helpful in treating depressive patients.
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